Evidence Table I2: DISCRETE outcomes for class ANTI-BACTERIAL (ORAL)./KERATOLYTIC (TOPICAL).

Trial #

Method Info

Discrete Outcome Name (Units)

Definition/Comments

Between

P-value

Follow- Treatment Comparator

up (wks)

Comparison Attribute: Number of patient Attribute: Number of patients

Sulfur-resorcinol + cotrimoxazole Placebo + cotrimoxazole I.01.01

Severity change (severity) Very good (>75% reduction) 7 0.001

Good (50-75% reduction) 15

Moderate (25-49% reduction) 24

Poor (<25% reduction) 8

Very good (>75% reduction) 2

Good (50-75% reduction) 6

Moderate (25-49% reduction) 16

Poor (<25% reduction) 12

No change/worse 12

126

Parallel 

N=211

È Short (5.

No change/worse 4

Comedones change (count) Very good + good (>50% ) 23 0.001

Less than very good improved 

(50%) 29

Very good + good (>50%) 6

Less than very good improved 

(50%) 34

Mid (7)

Desquamation Absent 52

Slight 18

Moderate 1

Withdraw 0

Absent 57

Slight 14

Moderate 0

Withdraw 0

Mid (7)

Erythema Absent 39

Slight 15

Moderate 6

Withdraw 5

Absent 47

Slight 2

Moderate 2

Withdraw 0

Mid (7)

Papules change (count) Very good + good improved 0.001

(>50%) 22

Less than very good (<50%) 30

Very good + good improved (>50%) 

6

Less than very good (<50%) 31

Mid (7)

Pustules change (count) Very good + good (>50%) 26 NS

Less than very good improved 

(<50%) 26

Very good + good (>50%) 19

Less than very good improved 

(<50%) 18

Mid (7)

Severity change (severity) Very good (>75% reduction) 8 0.001

Good (50-75% reduction) 24

Moderate (25-49% reduction) 15

Poor (1-24% reduction) 16

Very good (>75% reduction) 4

Good (50-75% reduction) 5

Moderate (25-49% reduction) 20

Poor (1-24% reduction) 20

Unchanged (0% reduction) 17

Worse (<0% reduction) 5

Mid (7)

Unchanged (0% reduction) 4

Worse (<0% reduction) 4

Sulfur-resorcinol + cotrimoxazole Tretinoin + cotrimoxazole I.01.02

TRIAL: -presence of positive or negative methodological features (see Summary Table). "Mild/mod," etc., -our assessment of entry severity of study patients. "P"- to parallel study, "S"-split face design. BETWEEN 

P-VALUE: comparison between Target and Comparator arms.

Evidence Table I DISCRETE: Page 1 of 2

ÈÍ
Trial #

Method Info

Discrete Outcome Name (Units)

Definition/Comments

Between

P-value

Follow- Treatment Comparator

up (wks)

Comparison Attribute: Number of patient Attribute: Number of patients

Severity change (severity) Very good (>75% reduction) 7 0.001

Good (50-75% reduction) 15

Moderate (25-49% reduction) 24

Poor (<25% reduction) 8

Very good (>75% reduction) 20

Good (50-75% reduction) 22

Moderate (25-49% reduction) 12

Poor (<25% reduction) 8

No change/worse 1

126

Parallel 

N=211

È Short (5.

No change/worse 4

Comedones change (count) Very good + good (>50% ) 23 0.001

Less than very good improved 

(50%) 29

Very good + good (>50%) 42

Less than very good improved 

(50%) 17

Mid (7)

Desquamation Absent 52

Slight 18

Moderate 1

Withdraw 0

Absent 33

Slight 21

Moderate 14

Withdraw 0

Mid (7)

Erythema Absent 39

Slight 15

Moderate 6

Withdraw 5

Absent 17

Slight 34

Moderate 24

Withdraw 19

Mid (7)

Papules change (count) Very good + good improved 0.001

(>50%) 22

Less than very good (<50%) 30

Very good + good improved (>50%) 

41

Less than very good (<50%) 18

Mid (7)

Pustules change (count) Very good + good (>50%) 26 NS

Less than very good improved 

(<50%) 26

Very good + good (>50%) 44

Less than very good improved 

(<50%) 15

Mid (7)

Severity change (severity) Very good (>75% reduction) 8 0.001

Good (50-75% reduction) 24

Moderate (25-49% reduction) 15

Poor (1-24% reduction) 16

Very good (>75% reduction) 32

Good (50-75% reduction) 17

Moderate (25-49% reduction) 7

Poor (1-24% reduction) 10

Unchanged (0% reduction) 1

Worse (<0% reduction) 2

Mid (7)

Unchanged (0% reduction) 4

Worse (<0% reduction) 4

TRIAL: -presence of positive or negative methodological features (see Summary Table). "Mild/mod," etc., -our assessment of entry severity of study patients. "P"- to parallel study, "S"-split face design. BETWEEN 

P-VALUE: comparison between Target and Comparator arms.

Evidence Table I DISCRETE: Page 2 of 2

ÈÍ